PSMA PET for Prostate Cancer

The PSMA PET for prostate cancer is used at the Clinic in two scenarios: to detect relapses after treatment and to determine the extent of the disease at the time of diagnosis.

It allows us to detect recurrences or metastases of prostate cancer with PSA levels less than or equal to 0.2 ng/ml, a minimum value at which it is able to accurately localize the disease. This allows us to perform targeted therapies, so that the response is much more favorable and prolonged.

The detection of the location of relapses after radical surgery, radiotherapy or both allows for, after confirming the presence of tumour with a fusion biopsy, the application of minimally invasive targeted treatments using robotic surgery, transurethral resection, high-rate brachytherapy or irreversible electroporation, depending on the location and characteristics of the tumour.

The Clinic is the first centre in Spain and one of the first in Europe that has managed to rescue patients with relapses after failed surgery and radiotherapy, without sequelae, thanks to the abovementioned multidisciplinary approaches.

In the evaluation of the extent of the disease at the time of diagnosis, PET PSMA detects advanced disease at an early stage. This provides patients with earlier systemic treatments combined with treatment of local disease and stereotactic radiotherapy of metastases when this is appropriate.

PSMA for prostate cancer has the additional benefit of being used as a teragnostic agent. Teragnosis is the use of the same molecule for diagnosis and treatment. In the case of PSMA, it can be used together with Gallium or Fluor, for diagnosis, as indicated above, or with 177Lu (Lutetium) for treatment of the same lesions detected at diagnosis.

This type of therapy has proven its efficacy in patients with castration-resistant prostate cancer that shows limited response to other therapies, both in terms of increasing survival and improving symptomatology.